Mirikizumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Mirikizumab. Educational only — not medical advice.
Labeled uses
OMVOH is indicated for the treatment of: moderately to severely active ulcerative colitis in adults. moderately to severely active Crohn's disease in adults.
Source: FDA labeling via NIH DailyMed (set 472cbe04…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.